NCT03665155: Phase 1/2 - PET Imaging MM with 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Ab
- Completed
- Dec 30, 2018
- 1 min read
Updated: May 26, 2022
NCT03665155: Phase 1/2 - PET Imaging MM with 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Ab
The purpose of this study is to test 89Zr-DFO-daratumumab, a new imaging agent, to demonstrate its safety and ability to take pictures of the myeloma.
Phase I/II study with the goal to assess the feasibility of using the anti-CD38 monoclonal antibody daratumumab, labeled with Zirconium-89 (89Zr ) through deferoxamine (DFO), known as 89Zr-DFO-daratumumab, for PET imaging of multiple myeloma.
ClinicalTrials.gov Identifier: NCT03665155
CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging
Radiology; 2020 Jun
- New York: Memorial Sloan-Kettering Cancer Center New York